Vasopressin is suggested as an adjunct to norepinephrine in patients with septic shock. However, after vasopressin was rebranded in November 2014, its cost exponentially increased. Utilization patterns of vasopressin after its rebranding are unclear. The objective of this study was to determine if there is an association between the rebranding of vasopressin in November 2014 and its utilization in vasopressor-dependent patients with severe sepsis or septic shock.

中文翻译：

---

感染性休克患者加压素品牌重塑与使用之间的关联。

建议在感染性休克患者中加压素作为去甲肾上腺素的辅助药物。然而，在 2014 年 11 月加压素更名后，其成本呈指数级增长。品牌重塑后加压素的使用模式尚不清楚。本研究的目的是确定 2014 年 11 月加压素的品牌重塑与其在严重脓毒症或感染性休克的血管加压药依赖患者中的应用之间是否存在关联。